aceThe use of artificial intelligence in patent ductus arteriosus diagnosis and treatment: a systematic scoping review
Background. Background and objectives: Patent ductus arteriosus (PDA) is a common congenital cardiac condition, especially in premature infants, and is associated with significant morbidity and mortality. Artificial intelligence (AI) has emerged as a promising tool to aid clinicians in diagnosing PDA and guiding treatment decisions amidst this uncertainty. Methods. A literature search (up to December 2025) was conducted in PubMed, Scopus, and Web of Science for peer-reviewed studies on AI (including machine lear…
Imaging-based deep learning models for patent ductus arteriosus diagnosis and outcome prediction in preterm neonates often reached an AUC above 0.80, outperforming approaches using tabular data.
Overall study quality was moderate, with limited external validation and data transparency, so the reported performance may not generalize and clinical benefits remain unproven.
Evidence
- Peer-reviewedThe Turkish Journal of Pediatrics2026-10-21
How should this claim be treated?
Truvace Impact Record TRV-2026-2162, v1: “The use of artificial intelligence in patent ductus arteriosus diagnosis and treatment: a systematic scoping review.” Truvace, 2026-10-22. /record/TRV-2026-2162 (accessed at citation time). sha256 b36447d363b45fad…
Calibration history
Every change to this record since certification, in the open. None yet — the reading has held since it entered the record.
Certified into the record
How to verify without trusting this page
Fetch the canonical text of any version from /api/record/TRV-2026-2162 and hash it yourself — for example shasum -a 256 on the saved canonical field. The result must equal content_hash, and each version’s text ends with prev:followed by the prior version’s hash (version 1 chains to 64 zeros). If a single character of any version had been altered since certification, the chain would not reproduce.